Propensity score–matched analysis of adjuvant chemotherapy for stage I non–small cell lung cancer Yasuhiro Tsutani, MD, PhD, Yoshihiro Miyata, MD, PhD,

Slides:

Advertisements

Similar presentations

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

Advertisements

Manuel J. Antunes, MD, PhD, DSc

Stephen R. Broderick, MD, MPHS

Michael F. Nentwich, MD, Benjamin A. Bohn, MD, Faik G

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus Yang Zhao, MD, ZhiJun Dai,

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

Michael Y. Chang, MD, MPH, Steven J. Mentzer, MD, Yolonda L

Local recurrence after surgery for non–small cell lung cancer: A recursive partitioning analysis of multi-institutional data Chris R. Kelsey, MD, Kristin.

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection Morihito Okada,

Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non–small cell lung cancer

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system Shamus R.

Clinical Prognosis of Superior Versus Basal Segment Stage I Non-Small Cell Lung Cancer Yoshinori Handa, MD, Yasuhiro Tsutani, MD, PhD, Norifumi Tsubokawa,

Which patients should be operated on after induction chemotherapy for N2 non–small cell lung cancer? Analysis of a 7-year experience in 175 patients

Multicenter analysis of high-resolution computed tomography and positron emission tomography/computed tomography findings to choose therapeutic strategies.

Radical sublobar resection for small-sized non–small cell lung cancer: A multicenter study Morihito Okada, MD, PhD, Teruaki Koike, MD, PhD, Masahiko.

Pleomorphic carcinoma of the lung: A surgical outcome

Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism–related genes Ruben Pio, PharmD, PhD, Jackeline.

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer Kyong-Ah Yoon,

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

Role of lymphatic invasion in the prognosis of patients with clinical node-negative and pathologic node-positive lung adenocarcinoma Takahiro Mimae,

Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non–small cell lung cancer: A propensity-matched analysis Whitney S. Brandt, MD, Wanpu.

Sleeve lung resection for lung cancer: Analysis according to the type of procedure Kazumichi Yamamoto, MD, Yoshihiro Miyamoto, MD, Akihiro Ohsumi, MD,

Survival related to lymph node involvement in lung cancer after sleeve lobectomy compared with pneumonectomy Morihito Okada, MD, Hiroyuki Yamagishi,

Victor van Berkel, MD, PhD

Multimodality therapy for locally advanced thymomas: A propensity score–matched cohort study from the European Society of Thoracic Surgeons Database

How should we treat air leaks?

Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial Stacey.

Metformin exposure is associated with improved progression-free survival in diabetic patients after resection for early-stage non–small cell lung cancer

Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.

Impact of Lepidic Component Occupancy on Effects of Adjuvant Chemotherapy for Lung Adenocarcinoma Shinsuke Sasada, MD, PhD, Yoshihiro Miyata, MD, PhD,

The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma Yasuhiro Tsutani, MD, PhD, Yoshihiro.

The lord of the rings Antonio Miceli, MD, PhD

Esophagectomy versus endoscopic resection for patients with early-stage adenocarcinoma: Mercedes versus Tesla Toni Lerut, MD The Journal of Thoracic.

A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non–small cell lung cancer Christopher.

Segmentectomy for selected cT1N0M0 non–small cell lung cancer: A prospective study at a single institute Hiroaki Nomori, PhD, Takeshi Mori, PhD, Koei.

Lung adenocarcinoma: Are skip N2 metastases different from non-skip?

Yang Zhang, MD, Haiquan Chen, MD, PhD

Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non–small cell.

Solid tumors versus mixed tumors with a ground-glass opacity component in patients with clinical stage IA lung adenocarcinoma: Prognostic comparison using.

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Innovation and science: The future of valve design

It's not “just a shunt” but sometimes it should be…

A first start for lung transplantation?

Stephen R. Broderick, MD, MPHS

Joseph A. Dearani, MD, Michael J. Ackerman, MD, PhD

Are discordant positron emission tomography and pathological assessments of the mediastinum in non–small cell lung cancer significant? Daniel J. Tandberg,

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Video-assisted mediastinoscopic lymphadenectomy is associated with better survival than mediastinoscopy in patients with resected non–small cell lung.

Patterns of care in hilar node-positive (N1) non–small cell lung cancer: A missed treatment opportunity? Matthew J. Bott, MD, Aalok P. Patel, BS, Vivek.

Sebastien Gilbert, MD, Andre B. Martel, BSc, Andrew J

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

The future of cardiac surgery training: A survival guide

Linda W. Martin, MD, MPH, FCCP, FACS, Gail E

Robert J. Cerfolio, MD, FACS, FCCP, Ayesha S. Bryant, MSPH, MD

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

Role of Positron Emission Tomography/Computed Tomography Findings for Adjuvant Chemotherapy Indications in Stage T1b-2aN0M0 Lung Adenocarcinoma Shinsuke.

“The more things change…”: The challenges ahead

Aritoshi Hattori, MD, Kenji Suzuki, MD

Prognostic Role of Positron Emission Tomography and High-Resolution Computed Tomography in Clinical Stage IA Lung Adenocarcinoma Hirofumi Uehara, MD,

Salvage surgery for advanced non–small cell lung cancer after response to gefitinib Tomoyuki Hishida, MD, Kanji Nagai, MD, Tetsuya Mitsudomi, MD, Kohei.

Who should decide margin length in pulmonary excision of lung cancer?

Prognostic Role of Subtype Classification in Small-Sized Pathologic N0 Invasive Lung Adenocarcinoma Tomoharu Yoshiya, MD, Takahiro Mimae, MD, PhD, Yasuhiro.

Samuel Kim, MD The Journal of Thoracic and Cardiovascular Surgery

A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for.

Reappraise the advanced technique for tumor localization and sentinel lymph node assessment in clinical early-stage non–small cell lung cancer Chengwu.

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

Propensity score–matched analysis of adjuvant chemotherapy for stage I non–small cell lung cancer Yasuhiro Tsutani, MD, PhD, Yoshihiro Miyata, MD, PhD, Kei Kushitani, MD, PhD, Yukio Takeshima, MD, PhD, Masahiro Yoshimura, MD, PhD, Morihito Okada, MD, PhD The Journal of Thoracic and Cardiovascular Surgery Volume 148, Issue 4, Pages 1179-1185 (October 2014) DOI: 10.1016/j.jtcvs.2014.05.084 Copyright © 2014 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Flow chart for selection of patients for this study. The Journal of Thoracic and Cardiovascular Surgery 2014 148, 1179-1185DOI: (10.1016/j.jtcvs.2014.05.084) Copyright © 2014 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 A, In all patients, there was no significant difference in the recurrence-free survival (RFS) rates between patients who received adjuvant chemotherapy (5-year RFS rate, 76.3%; mean RFS rate, 78.1 months; 95% confidence interval [CI], 70.5-85.8 months) and those who did not (5-year RFS rate, 71.5%; mean RFS rate, 80.8 months; 95% CI, 77.5-84.0 months; P = .69). B, In all patients, there was no significant difference in the overall survival (OS) rates between patients who received adjuvant chemotherapy (5-year OS rate, 88.1%; mean OS rate, 89.6 months; 95% CI, 83.6-95.5 months) and those who did not (5-year OS rate, 71.5%; mean OS rate, 81.5 months; 95% CI, 88.0-90.8 months; P = .17). The Journal of Thoracic and Cardiovascular Surgery 2014 148, 1179-1185DOI: (10.1016/j.jtcvs.2014.05.084) Copyright © 2014 The American Association for Thoracic Surgery Terms and Conditions

Figure 3 A, In propensity score–matched pairs, 5-year recurrence-free survival (RFS) rates of 79.8% (mean RFS rate, 80.8 months; 95% confidence interval [CI], 72.8-88.7 months) and 62.0% (mean RFS rate, 68.9 months; 95% CI, 62.7-75.0 months) were identified for patients who received adjuvant chemotherapy and those who did not, respectively. B, In propensity score–matched pairs, 5-year overall survival (OS) rates of 89.3% (mean OS rate, 89.8 months; 95% CI, 82.9-96.7 months) and 75.2% (mean OS rate, 82.2 months; 95% CI, 76.4-88.1 months) were identified for patients who received adjuvant chemotherapy and those who did not, respectively. The Journal of Thoracic and Cardiovascular Surgery 2014 148, 1179-1185DOI: (10.1016/j.jtcvs.2014.05.084) Copyright © 2014 The American Association for Thoracic Surgery Terms and Conditions

Figure 4 A, There was no difference in the recurrence-free survival (RFS) rate between patients who received adjuvant chemotherapy and those who did not in the group with an invasive component size ≤2 cm: 5-year RFS rate, 78.9% (mean RFS rate, 85.1 months; 95% confidence interval [CI], 74.3-95.8 months) versus 81.4% (mean RFS rate, 89.2 months; 95% CI, 85.7-92.7 months; P = .90). B, There was a significant difference in the RFS rate between patients who received adjuvant chemotherapy and those who did not in the group with an invasive component size >2.0 cm: 5-year RFS rate, 74.4% (mean RFS rate, 74.0 months; 95% CI, 65.6-82.3 months) versus 55.2% (mean RFS rate, 64.0 months; 95% CI, 58.5-69.5 months; P = .015). C, There was no difference in the RFS rate between patients who received adjuvant chemotherapy and those who did not in the group without lymphatic invasion: 5-year RFS rate, 85.4% (mean RFS rate, 83.9 months; 95% CI, 74.1-93.7 months) versus 79.5% (mean RFS rate, 87.5 months; 95% CI, 84.2-90.7 months; P = .78). D, There was a significant difference in the RFS rate between patients who received adjuvant chemotherapy and those who did not in the group with lymphatic invasion: 5-year RFS rate, 63.3% (mean RFS rate, 62.7 months; 95% CI, 53.5-71.8 months) versus 44.8% (mean RFS rate, 57.4 months; 95% CI, 49.8-65.0 months; P = .05). LY, Positive lymphatic invasion. The Journal of Thoracic and Cardiovascular Surgery 2014 148, 1179-1185DOI: (10.1016/j.jtcvs.2014.05.084) Copyright © 2014 The American Association for Thoracic Surgery Terms and Conditions